246 related articles for article (PubMed ID: 20715160)
1. Risk of mortality in patients with cancer who experience febrile neutropenia.
Lyman GH; Michels SL; Reynolds MW; Barron R; Tomic KS; Yu J
Cancer; 2010 Dec; 116(23):5555-63. PubMed ID: 20715160
[TBL] [Abstract][Full Text] [Related]
2. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
3. Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.
Chia VM; Page JH; Rodriguez R; Yang SJ; Huynh J; Chao C
Breast Cancer Res Treat; 2013 Apr; 138(2):621-31. PubMed ID: 23468242
[TBL] [Abstract][Full Text] [Related]
4. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
Laskey RA; Poniewierski MS; Lopez MA; Hanna RK; Secord AA; Gehrig PA; Lyman GH; Havrilesky LJ
Gynecol Oncol; 2012 Jun; 125(3):625-30. PubMed ID: 22426251
[TBL] [Abstract][Full Text] [Related]
5. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Kuderer NM; Dale DC; Crawford J; Cosler LE; Lyman GH
Cancer; 2006 May; 106(10):2258-66. PubMed ID: 16575919
[TBL] [Abstract][Full Text] [Related]
6. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430
[TBL] [Abstract][Full Text] [Related]
7. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
8. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
9. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.
Borg C; Ray-Coquard I; Philip I; Clapisson G; Bendriss-Vermare N; Menetrier-Caux C; Sebban C; Biron P; Blay JY
Cancer; 2004 Dec; 101(11):2675-80. PubMed ID: 15503313
[TBL] [Abstract][Full Text] [Related]
10. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia.
Rondinelli PI; Ribeiro Kde C; de Camargo B
J Pediatr Hematol Oncol; 2006 Oct; 28(10):665-70. PubMed ID: 17023827
[TBL] [Abstract][Full Text] [Related]
11. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
12. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
13. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection.
Ammann RA; Hirt A; Lüthy AR; Aebi C
Med Pediatr Oncol; 2003 Nov; 41(5):436-43. PubMed ID: 14515382
[TBL] [Abstract][Full Text] [Related]
14. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
Caggiano V; Weiss RV; Rickert TS; Linde-Zwirble WT
Cancer; 2005 May; 103(9):1916-24. PubMed ID: 15751024
[TBL] [Abstract][Full Text] [Related]
15. Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: results of the prospective multicenter SPOG 2003 FN study.
Lüthi F; Leibundgut K; Niggli FK; Nadal D; Aebi C; Bodmer N; Ammann RA
Pediatr Blood Cancer; 2012 Jul; 59(1):90-5. PubMed ID: 21837771
[TBL] [Abstract][Full Text] [Related]
16. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
17. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study.
Offidani M; Corvatta L; Malerba L; Marconi M; Bichisecchi E; Cecchini S; Manso E; Principi T; Gasparini S; Leoni P
Cancer; 2004 Aug; 101(3):567-77. PubMed ID: 15274070
[TBL] [Abstract][Full Text] [Related]
19. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
[TBL] [Abstract][Full Text] [Related]
20. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
